SCHEMBL144184

SCHEMBL144184

Oc1cc[c]c2cccnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 0.48
METAP1 P53582 2/20 0.48
COMT P21964 2/20 0.48
CHRM1 P11229 2/20 0.48
MMP2 P08253 2/20 0.48
TSHR P16473 2/20 0.48
ADRA1A P35348 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HTT P42858 4/20 0.47
SLC6A2 P23975 1/20 0.47
KDM4E B2RXH2 11/20 0.43
L3MBTL1 Q9Y468 5/20 0.43
HSP90AA1 P07900 5/20 0.43
LMNA P02545 4/20 0.43
MAPT P10636 4/20 0.43
IDO1 P14902 2/20 0.43
BRD4 O60885 2/20 0.43
MPI P34949 1/20 0.43
HSP90AB1 P08238 1/20 0.43
PSMB5 P28074 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8467497 0.84 METAP2 (0.48) METAP2METAP1COMTCHRM1MMP2
SCHEMBL6163578 0.76 LMNA (0.41) METAP2METAP1COMTCHRM1MMP2
SCHEMBL20264913 0.76 KDM4E (0.39) METAP2METAP1COMTCHRM1MMP2
SCHEMBL8391499 0.76 MAPT (0.42) MMP2TSHRHTTSLC6A2KDM4E
SCHEMBL789544 0.76 PSMD14 (0.43) MMP2TSHRADRA1AHTTSLC6A2
SCHEMBL6312154 0.76 KDM4E (0.38) METAP2METAP1COMTCHRM1MMP2
SCHEMBL9172751 0.75 MMP2 (0.49) METAP2METAP1COMTCHRM1MMP2
SCHEMBL2409957 0.72 CCR1 (0.37) METAP2METAP1COMTCHRM1MMP2
SCHEMBL22121642 0.72 LRRK2 (0.38) MMP2TSHRHTTKDM4EHSP90AA1
SCHEMBL20265329 0.72 LMNA (0.33) MMP2TSHRHTTKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101641332-B Aminated hydroxyquinoline derivatives for the treatment of cancer BIOPHARMED 2014-03-12 CN claimed
US-8058442-B2 Neuroprotective iron chelators and pharmaceutical compositions comprising them TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2011-11-15 US claimed
JP-4757024-B2 2011-08-24 JP claimed
US-20060234927-A1 Neuroprotective iron chelators and pharmaceutical compositions comprising them TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2006-10-19 US claimed
EP-1565185-A2 NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2005-08-24 EP claimed
EP-1465882-A4 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2005-04-06 EP claimed
EP-1465882-A2 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2004-10-13 EP claimed
WO-2004041151-A2 NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2004-05-21 WO claimed
US-6696473-B2 THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM X-CEPTOR THERAPEUTICS, INC. 2004-02-24 US claimed
WO-2003060078-A9 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2004-02-19 WO claimed
US-20030212111-A1 Heterocyclic modulators of nuclear receptors AKARNA THERAPEUTICS, LTD. (GB) 2003-11-13 US claimed
WO-2003060078-A2 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO claimed
EP-1189606-A2 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) 2002-03-27 EP claimed
WO-2000074664-A2 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2000-12-14 WO claimed
CN-101641332-B Aminated hydroxyquinoline derivatives for the treatment of cancer BIOPHARMED 2014-03-12 CN disclosed
US-20120058945-A1 NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) 2012-03-08 US disclosed
US-8058442-B2 Neuroprotective iron chelators and pharmaceutical compositions comprising them TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2011-11-15 US disclosed
US-4886733-A Photographic products and processes POLAROID CORPORATION (US) 1989-12-12 US disclosed
US-3929797-A Photographic processes and products employing 8-quinolinol phthaleins as optical filter agents POLAROID CORP 1975-12-30 US disclosed
US-3816123-A PHOTOGRAPHIC PROCESSES AND PRODUCTS EMPLOYING 8-QUINOLINOL PHTHALEINS AS OPTICAL FILTER AGENTS POLAROID CORP 1974-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058945-A1 NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FECH, HMOX1, FTH1 METAP2 3021/4885METAP1 1862/4885COMT 1313/4885
US-20060234927-A1 Neuroprotective iron chelators and pharmaceutical compositions comprising them FECH, HMOX1, FTH1 METAP2 3014/4885METAP1 1831/4885COMT 1071/4885
US-20030212111-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 METAP2 4242/4885METAP1 4271/4885COMT 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.